Skip to main content
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
Betacellulin drives therapy resistance in glioblastoma.
Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype.
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.